A couple of relevant papers on Nucuferine specifically,I think the main headline here is it resembles aspects of the pharmacology of atypical antipsychotics (in rats) although nuciferine is
not pharmacologically identical to aripiprazole or clozapine. However Blue Lotus also has Apomorphine which also acts on D2 receptor so whether it's worth trying Nucuferine powder on it's own is another question....
In Vitro and In Vivo Characterization of the Alkaloid Nuciferine
The sacred lotus (Nelumbo nucifera) contains many phytochemicals and has a history of human use. To determine which compounds may be responsible for reported psychotropic effects, we used in silico predictions of the identified phytochemicals. ...
pmc.ncbi.nlm.nih.gov
use
https://www.tesble.com/ to read it if you don't have an account
"Results
Nuciferine shares a receptor profile similar to aripiprazole-like antipsychotic drugs. Nucifer-
ine was an antagonist at 5-HT2A, 5-HT2C, and 5-HT2B, an inverse agonist at 5-HT7, a partial
agonist at D2, D5 and 5-HT6, an agonist at 5-HT1A and D4 receptors, and inhibited the dopa-
mine transporter. In rodent models relevant to antipsychotic drug action, nuciferine blocked
head-twitch responses and discriminative stimulus effects of a 5-HT2A agonist, substituted
for clozapine discriminative stimulus, enhanced amphetamine induced locomotor activity,
inhibited phencyclidine (PCP)-induced locomotor activity, and rescued PCP-induced dis-
ruption of prepulse inhibition without induction of catalepsy.
Conclusions
The molecular profile of nuciferine was similar but not identical to that shared with several
approved antipsychotic drugs suggesting that nuciferine has atypical antipsychotic-like
actions."
ChatGPT analysis of the table above, I asked it to
consider only receptors that were meaningfully activated
| Receptor | Nuciferine affinity / potency | Mechanism | Likely functional effects | Confidence / comments |
|---|
| D2 dopamine | Ki ~515 nM; EC50 ~65 nM | Partial agonist; also competitively reduces dopamine signaling | Modulates dopamine signaling rather than simply turning it on/off. Can potentially reduce excessive D2 signaling while retaining some activity; may affect motivation, salience, movement and psychotic-like signaling | Very high relevance. Emax ≈67% of dopamine. This is one of the strongest functional findings. (PubMed Central (PMC)) |
| 5-HT7 | Ki ~49.8 nM; EC50 ~150 nM | Inverse agonist | Suppresses constitutive 5-HT7 signaling. Could influence mood, cognition, sleep/circadian regulation and serotonergic processing | High relevance. Very strong binding and functional potency. (PubMed Central (PMC)) |
| 5-HT2C | Ki ~60.5 nM; IC50 ~131 nM | Antagonist | Removes some 5-HT2C-mediated inhibition of dopaminergic/noradrenergic pathways; can influence appetite, arousal, mood and dopamine release | High relevance. Functional antagonist activity demonstrated. (PubMed Central (PMC)) |
| 5-HT2A | Ki ~312 nM; IC50 ~478 nM | Antagonist | Reduces 5-HT2A signaling, particularly cortical serotonergic signaling; can reduce perceptual/cognitive effects mediated through 5-HT2A | High relevance. Nuciferine blocked DOI-induced head-twitch behavior in mice, a commonly used 5-HT2A-mediated model. (PubMed Central (PMC)) |
| 5-HT6 | Ki ~268 nM; EC50 ~700 nM | Very-low-efficacy partial agonist (~17.3% maximal response) | Probably relatively modest 5-HT6 activation; potentially affects cognition, learning and neurotransmitter release | Moderate. Strong enough binding, but the functional response is weak. (PubMed Central (PMC)) |
| 5-HT2B | Ki ~41 nM; IC50 ~1,000 nM | Antagonist | Blocks peripheral/CNS 5-HT2B signaling; effects on mood/perception are probably less important than 5-HT2A/2C | Binding is extremely strong, functional potency considerably weaker. 5-HT2B is also a receptor where peripheral effects matter. (PubMed Central (PMC)) |
| D1 dopamine | Ki ~752 nM | Functional action not established in this study | Could potentially alter D1-mediated excitation in corticostriatal circuits, affecting cognition, motivation and motor processes | Uncertain. Binding was demonstrated, but no functional assay was performed. (PubMed Central (PMC)) |
| D3 dopamine | Ki ~741 nM | Functional action not established | Potential modulation of mesolimbic dopamine signaling; theoretically relevant to reward, motivation and salience | Uncertain. Binding ≠ demonstrated agonism/antagonism. (PubMed Central (PMC)) |
| 5-HT1D | Ki ~518 nM | Functional action not established | Could modify serotonin release, since 5-HT1D receptors function partly as inhibitory autoreceptors/heteroreceptors | Uncertain. Binding demonstrated, functional direction unknown. (PubMed Central (PMC)) |
| α2B adrenergic | Ki ~687 nM | Functional action not established | Potential modulation of noradrenergic signaling; could theoretically influence arousal, vascular tone and CNS signaling | Uncertain. No functional assay in this study. (PubMed Central (PMC)) |
| α2C adrenergic | Ki ~693 nM | Functional action not established | Potential effects on norepinephrine/dopamine regulation, cognition, attention and motor circuits | Uncertain. Binding demonstrated but direction of effect unknown. (PubMed Central (PMC)) |
The receptors I would not put in the “likely perceptually important” group
There are a few that deserve special mention because they can look important from the heatmap but probably shouldn't be interpreted that way:
D4 — EC50 ~2 µM
Nuciferine is an agonist, but its functional potency was ~2 µM. That's substantially weaker than D2/5-HT7/5-HT2C. It could become relevant at sufficiently high concentrations, but I wouldn't put it in the strongest-effect tier.
D5 — EC50 ~2.6 µM
Partial agonist (~50% maximal response), again substantially weaker than D2. It may contribute at higher exposure but isn't likely to dominate the profile.
5-HT1A — EC50 ~3.2 µM
Nuciferine is an agonist, but its functional potency is relatively low despite its excellent binding affinity (
Ki 77 nM). This distinction is important:
it binds very well but activates the receptor relatively weakly in the assay.
DAT
The interesting finding here is actually quite unusual. Nuciferine didn't behave as a conventional DAT blocker in the experiments. In DAT-expressing cells, it increased dopamine uptake by ~60%, with an apparent EC50 of
1.8 nM in that particular assay. However, the effect disappeared when DAT and VMAT2 were expressed together, so interpreting this as straightforward “DAT activation” would be misleading.
If we're specifically asking: “What could I actually feel?”
I'd rank the
functional targets roughly like this:
1. D2 — probably the most important dopamine component
Partial agonism + antagonism of dopamine signaling.
This is a very interesting pharmacological arrangement. Nuciferine can activate D2 receptors, but because it is only a partial agonist, it can also compete with dopamine and
reduce the response when dopamine concentrations are high.
The authors measured ~67% of dopamine's maximal D2 response, compared with ~50% for aripiprazole in the cited comparison.
Potential consequences include:
- reduced excessive dopaminergic signaling
- altered salience/reward processing
- changes in motivation
- changes in locomotor activity
- potentially reduced psychotic-like signaling
- potentially some sedation or emotional flattening at sufficient exposure
This is
not equivalent to D2 blockade, though.
2. 5-HT7 — very strong serotonergic component
Nuciferine has
~50 nM binding affinity and ~150 nM functional potency here. It is an
inverse agonist, meaning it can suppress baseline receptor activity rather than merely preventing serotonin from activating it.
This could potentially contribute to:
- altered mood
- altered cognition
- changes in sleep/wake regulation
- changes in anxiety
- altered sensory processing
But translating a 150-nM cellular potency into a subjective human effect is not straightforward.
3. 5-HT2A — probably the most relevant receptor for perception
This is the one I'd pay particular attention to if by
“perception” you mean visual/sensory/cognitive perception.
Nuciferine is a
5-HT2A antagonist, with:
- Ki ≈ 312 nM
- IC50 ≈ 478 nM
Importantly, this wasn't merely a binding prediction: nuciferine
blocked the head-twitch response produced by the 5-HT2A agonist DOI in mice.
So its likely effect is
not psychedelic activation of perception. It's essentially the opposite direction at this receptor:
reducing 5-HT2A signaling.
That could theoretically mean:
less sensory amplification → less perceptual distortion → less psychedelic-like signaling
rather than hallucinations or visual enhancement.
4. 5-HT2C — strong modulatory component
At
~60 nM Ki / 131 nM IC50, this is another relatively high-affinity interaction. Nuciferine is an antagonist.
Because 5-HT2C receptors regulate dopamine and norepinephrine circuits, blocking them can indirectly
increase dopaminergic/noradrenergic signaling in some pathways.
This makes the overall pharmacology more complicated than simply saying “nuciferine suppresses dopamine.”
The important distinction: affinity vs actual effect
I'd divide the table into three levels:
Tier 1 — strongest evidence for meaningful CNS effects
D2 → 5-HT7 → 5-HT2C → 5-HT2A
These are the four I'd focus on.
There's experimental evidence that nuciferine actually
does something functional at each:
- D2: partial agonist
- 5-HT7: inverse agonist
- 5-HT2C: antagonist
- 5-HT2A: antagonist
That is much more compelling than merely seeing a red/green/blue cell in the binding heatmap.
Tier 2 — potentially relevant but probably secondary
5-HT6 → 5-HT2B
5-HT6 has 700-nM potency but only ~17% efficacy, while 5-HT2B has ~1-µM functional potency despite very strong binding.
Tier 3 — potentially relevant binding, but unknown functional direction
D1, D3, 5-HT1D, α2B, α2C
These are where I'd be particularly cautious. A receptor's Ki tells us:
"Nuciferine can bind this receptor."
It does
not tell us:
"Nuciferine activates this receptor."
It could be an agonist, antagonist, inverse agonist, biased agonist, etc.
Discovery of eight alkaloids with D1 and D2 antagonist activity in leaves of Nelumbo nucifera Gaertn. Using FLIPR assays
"
Results: Alkaloids in the lotus leaves were the bioactive phytochemicals and inhibited dopamine from accessing the D1 and D2 receptors. All eight compounds functioned as D1-receptor antagonists and except N-nornuciferine, seven alkaloids functioned as D2-receptor antagonists. (S)-coclaurine and (R)-coclaurine are optical isomers and antagonized both D1 and D2 with equivalent potencies, suggesting that the optical rotation of the methylene linker in the monobenzyl isoquinoline backbone did not influence their activity. Among the eight alkaloids, O-nornuciferine was the potent antagonist to both receptors (the lowest IC50 values, D1: 2.09 ± 0.65 μM and D2: 1.14 ± 0.10 μM) while N-nornuciferine was found to be the least potent as it moderately antagonized D1 and was inactive on D2. O-nornuciferine was also a 5-HT2A antagonist (IC50~20 μM) while N-nornuciferine had no activity. These hinted the importance of a methyl group attached to the nitrogen atom in the aporphine backbone. Armepavine showed a nearly 10-fold selectivity to D2.
Conclusions: In this work, eight alkaloids were isolated from the leaves of Nelumbo nucifera Gaertn. and assayed on the D1 and D2 receptors. They were D1/D2 antagonists with IC50 values in the mid- to low-micromolar range and O-nornuciferine was the most potent alkaloid among the eight. This family of alkaloids was biochemically evaluated on the dopamine receptors by the same platform for the first time."
www.acslab.com
recovered.org
. Very relaxing.
"
